Chr. Hansen Holding A/S (CHYHY) Income Statement Analysis

See more : Israel Shipyards Industries Ltd (ISHI.TA) Income Statement Analysis – Financial Results

Complete financial analysis of Chr. Hansen Holding A/S (CHYHY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chr. Hansen Holding A/S, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.

You may be interested

Chr. Hansen Holding A/S (CHYHY)

Industry: Chemicals - Specialty

Sector: Basic Materials

Website: https://www.chr-hansen.com

About Chr. Hansen Holding A/S

Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. It operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products in the food industry, primarily in the dairy industry. The Health & Nutrition segment produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula, animal feed, and plant protection industries. It has a strategic collaboration with UPL Ltd. to develop and commercialize microbial-based bio solutions for sustainable agriculture. The company was founded in 1843 and is headquartered in Hørsholm, Denmark.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	1.33B	1.22B	1.08B	970.00M	1.16B	1.10B	1.06B	948.90M	858.60M	756.20M	738.40M	698.70M	635.60M	575.50M	511.20M	476.69M	444.78M
Cost of Revenue	610.12M	541.50M	464.00M	386.00M	511.10M	496.80M	484.40M	443.50M	412.20M	364.90M	353.60M	339.10M	326.90M	290.40M	269.12M	247.80M	241.32M
Gross Profit	722.14M	676.50M	613.40M	584.00M	650.00M	600.60M	578.10M	505.40M	446.40M	391.30M	384.80M	359.60M	308.70M	285.10M	242.08M	228.89M	203.47M
Gross Profit Ratio	54.20%	55.54%	56.93%	60.21%	55.98%	54.73%	54.41%	53.26%	51.99%	51.75%	52.11%	51.47%	48.57%	49.54%	47.36%	48.02%	45.75%
Research & Development	99.64M	96.80M	90.10M	76.20M	79.40M	73.40M	71.40M	62.50M	51.00M	43.20M	42.90M	35.70M	28.20M	25.00M	22.54M	22.13M	23.08M
General & Administrative	86.00M	82.00M	73.10M	53.30M	71.10M	70.40M	70.90M	65.90M	61.30M	53.90M	55.80M	51.60M	46.10M	44.40M	41.40M	39.56M	36.10M
Selling & Marketing	182.90M	173.90M	154.80M	135.10M	158.50M	139.30M	134.20M	112.70M	101.70M	92.70M	96.10M	89.60M	78.90M	73.10M	66.02M	65.44M	63.08M
SG&A	268.47M	255.90M	227.90M	188.40M	229.60M	209.70M	205.10M	178.60M	163.00M	146.60M	151.90M	141.20M	125.00M	117.50M	107.42M	104.99M	99.18M
Other Expenses	0.00	-2.00M	-2.70M	-7.50M	-2.20M	-2.70M	-5.50M	-3.50M	-100.00K	-3.30M	-2.50M	-2.30M	-3.70M	-700.00K	-1.76M	-1.48M	-2.01M
Operating Expenses	368.11M	350.70M	315.30M	257.10M	306.80M	280.40M	271.00M	237.60M	213.90M	186.50M	192.30M	174.60M	149.50M	141.80M	128.19M	125.64M	120.26M
Cost & Expenses	978.24M	892.20M	779.30M	643.10M	817.90M	777.20M	755.40M	681.10M	626.10M	551.40M	545.90M	513.70M	476.40M	432.20M	397.31M	373.44M	361.57M
Interest Income	29.00M	2.20M	1.90M	3.70M	5.10M	1.60M	400.00K	700.00K	800.00K	900.00K	500.00K	32.40M	37.60M	38.70M	9.57M	41.30M	32.75M
Interest Expense	28.95M	10.50M	20.40M	13.10M	14.30M	8.70M	8.00M	8.70M	7.40M	8.40M	7.30M	45.10M	48.50M	105.70M	116.10M	112.50M	115.02M
Depreciation & Amortization	113.72M	101.10M	112.50M	92.50M	69.00M	63.80M	61.00M	56.20M	53.90M	51.90M	56.50M	50.50M	42.50M	62.90M	40.58M	48.81M	40.94M
EBITDA	467.75M	405.20M	374.20M	387.18M	364.76M	371.40M	362.10M	318.80M	283.30M	246.20M	242.10M	267.90M	239.30M	182.00M	152.98M	144.55M	115.96M
EBITDA Ratio	35.11%	34.65%	36.08%	41.80%	35.30%	33.68%	34.08%	33.60%	34.20%	33.69%	32.79%	38.34%	37.65%	31.62%	32.09%	30.32%	26.07%
Operating Income	354.03M	320.90M	276.20M	313.00M	340.90M	320.20M	305.70M	255.60M	232.50M	195.10M	192.50M	185.00M	159.20M	119.10M	109.41M	95.74M	75.03M
Operating Income Ratio	26.57%	26.35%	25.64%	32.27%	29.36%	29.18%	28.77%	26.94%	27.08%	25.80%	26.07%	26.48%	25.05%	20.70%	21.40%	20.08%	16.87%
Total Other Income/Expenses	-46.53M	-28.00M	-51.00M	-17.40M	10.10M	-24.10M	-16.20M	-30.40M	-12.80M	-22.50M	-15.80M	-13.00M	-10.90M	-67.00M	-106.53M	-71.20M	-82.27M
Income Before Tax	307.51M	292.90M	247.10M	295.60M	324.80M	296.10M	290.90M	239.40M	219.70M	181.30M	176.70M	172.30M	148.30M	52.10M	2.88M	24.54M	-7.25M
Income Before Tax Ratio	23.08%	24.05%	22.93%	30.47%	27.97%	26.98%	27.38%	25.23%	25.59%	23.98%	23.93%	24.66%	23.33%	9.05%	0.56%	5.15%	-1.63%
Income Tax Expense	70.19M	67.80M	48.40M	64.00M	74.60M	67.90M	66.90M	55.60M	57.20M	49.10M	36.90M	41.00M	34.10M	32.40M	18.84M	17.30M	-1.21M
Net Income	226.64M	225.10M	198.70M	245.00M	250.20M	228.20M	224.00M	183.80M	162.50M	132.20M	137.80M	129.30M	118.60M	19.20M	-18.36M	43.58M	-12.75M
Net Income Ratio	17.01%	18.48%	18.44%	25.26%	21.55%	20.79%	21.08%	19.37%	18.93%	17.48%	18.66%	18.51%	18.66%	3.34%	-3.59%	9.14%	-2.87%
EPS	1.72	0.43	0.38	0.47	0.47	0.43	0.43	0.35	0.31	0.25	0.26	0.24	0.22	0.04	-0.05	0.08	-0.02
EPS Diluted	1.72	0.43	0.38	0.47	0.47	0.43	0.42	0.35	0.31	0.25	0.26	0.24	0.22	0.04	-0.05	0.08	-0.02
Weighted Avg Shares Out	131.98M	526.85M	526.85M	526.93M	526.88M	526.55M	525.80M	521.60M	522.78M	528.29M	525.79M	538.72M	540.56M	436.77M	403.30M	540.90M	540.90M
Weighted Avg Shares Out (Dil)	131.98M	527.57M	527.42M	527.67M	527.56M	527.22M	532.45M	526.93M	526.72M	530.08M	530.27M	546.27M	541.92M	436.91M	403.30M	540.90M	540.90M

Chr. Hansen: Still Somewhat Undervalued After Its Outperformance

December 26, 2023seekingalpha.com

Chr. Hansen Holding A/S is a Danish company with above-average growth potential in the enzymes business. The company recorded strong financial performance with 16% organic revenue growth and double-digit growth in core segments. The pending merger with Novozymes is expected...

Chr. Hansen Holding A/S (CHYHY) Q4 2023 Earnings Call Transcript

October 12, 2023seekingalpha.com

Chr. Hansen Holding A/S (OTCPK:CHYHY) Q4 2023 Earnings Conference Call October 12, 2023 4:00 AM ET Company Participants Mauricio Graber - President and Chief Executive Officer Lise Skaarup Mortensen - Executive Vice President and Chief Financial Officer Conference Call Participants...

Chr. Hansen Holding A/S Interim Report Q4 2022/23

October 12, 2023globenewswire.com

October 12, 2023 – Company announcement no. 9 Strong performance for the quarter despite a challenging environment Statement by CEO Mauricio Graber: “Supported by a strong Q4 performance, Chr.

Chr. Hansen: Not A Great Performance, But Looking Forward

July 20, 2023seekingalpha.com

Danish bioscience company Chr. Hansen, which specializes in the commercial production of enzymes, has impressive gross margins of over 54% and net margins of over 17%. Despite weak market trends, the company has reported near-double-digit organic revenue growth, solid EBIT...

Chr. Hansen Holding A/S (CHYHY) Q3 2022 Earnings Call Transcript

July 6, 2023seekingalpha.com

Chr. Hansen Holding A/S (OTCPK:CHYHY) Q3 2022 Earnings Conference Call July 6, 2023 4:00 AM ET Company Participants Mauricio Graber - President and Chief Executive Officer Lise Mortensen - Executive Vice President and Chief Financial Officer Conference Call Participants Alex...

1 2

Source: https://incomestatements.info
Category: Stock Reports

Chr. Hansen Holding A/S (CHYHY) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories